NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease


Learn how Nexviazyme can help your ERT-Naive and ERT-Experienced Patients with late-onset Pompe disease (LOPD)1

Learn more

ERT=enzyme replacement therapy.

Start your patients with LOPD on NEXVIAZYME

Learn how NEXVIAZYME can help your ERT-naive and ERT-experienced patients with LOPD.

Learn about late-onset Pompe disease

Pompe disease is a degenerative
muscle disease with a difficult-to-predict decline.2-7

The quickstart program image

The QuickStart Program

Transitioning your eligble patients to NEXVIAZYME
can be a seamless process.


Sanofi Genzyme also offers co-pay assistance and charitable access programs for eligible patients.

The Co-Pay Assistance Program helps individuals in the United States who are prescribed NEXVIAZYME pay for their eligible out‑of‑pocket drug and infusion‑related expenses (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.), including co‑pays,
co‑insurance, and deductibles.

To participate in this program, your patients must complete an enrollment application. Once your patients are enrolled, Sanofi Genzyme will cover 100% of their eligible out‑of‑pocket NEXVIAZYME drug costs, up to the program maximum.

Patient discussion guide

This self-addressment tool helps your patients monitor their current management plan and prepares them to have more meaningful conversations about their management goals and needs.

QuickStart Guide & Form

Everything you need to know to get your eligible patients enrolled.